# US 2003/0073658 A1 · 47619 and 47621, human ion channels, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073658 A1
- Document ID: US20030073658A1
- Status: Published application
- Kind: A1
- Application number: 10/192,116
- Filed: 2002-07-10
- Published: 2003-04-17
- Earliest claimed: 2001-07-10
- Assignees: Millennium Pharmaceuticals, Inc.
- Inventors: Rory A.J. Curtis
- Web page: https://patentgrep.com/patent/US20030073658A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides isolated nucleic acid molecules, designated 47619 and 47621 nucleic acid molecules, which encode novel 47619 and 47621-related ion channel molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 47619 and 47621 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 47619 and 47621 gene has been introduced or disrupted. The invention still further provides isolated 47619 and 47621 proteins, fusion proteins, antigenic peptides and anti-47619 and 47621 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

## Claims

### Claim 1

An isolated nucleic acid molecule selected from the group consisting of:
a) a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 8, or SEQ ID NO: 10;
b) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 8, or SEQ ID NO: 10;
c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9;
d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO: 2 or SEQ ID NO: 9; and
e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 8, or SEQ ID NO: 10, or a complement thereof, under stringent conditions.

### Claim 2 (depends on 1)

The isolated nucleic acid molecule of claim 1, further comprising a fragment of at least 800 nucleotides of the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3.

### Claim 3 (depends on 1)

The isolated nucleic acid molecule of claim 1, further comprising a fragment of at least 1200 nucleotides of the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 3.

### Claim 4 (depends on 1)

The isolated nucleic acid molecule of claim 1, further comprising a fragment of at least 500 nucleotides of the nucleotide sequence of SEQ ID NO: 8 or SEQ ID NO: 10.

### Claim 5 (depends on 1)

The isolated nucleic acid molecule of claim 1, further comprising a fragment of at least 600 nucleotides of the nucleotide sequence of SEQ ID NO: 8 or SEQ ID NO: 10.

### Claim 6 (depends on 1)

The isolated nucleic acid molecule of claim 1, which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein the fragment comprises at least 300 contiguous amino acids of SEQ ID NO: 2.

### Claim 7 (depends on 1)

The isolated nucleic acid molecule of claim 1, which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 9, wherein the fragment comprises at least 200 contiguous amino acids of SEQ ID NO: 9.

### Claim 8 (depends on 1)

The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of:
a. a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 8, or SEQ ID NO: 10; and
b. a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9.

### Claim 9 (depends on 1)

The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.

### Claim 10 (depends on 1)

The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.

### Claim 11 (depends on 1)

A host cell which contains the nucleic acid molecule of claim 1.

### Claim 12 (depends on 11)

The host cell of claim 11 which is a mammalian host cell.

### Claim 13 (depends on 1)

A non-human mammalian host cell containing the nucleic acid molecule of claim 1.

### Claim 14

An isolated polypeptide selected from the group consisting of:
a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 80% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 8, or SEQ ID NO: 10, or a complement thereof;
b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 8, or SEQ ID NO: 10; and
c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO: 2 or SEQ ID NO: 9.

### Claim 15 (depends on 14)

The isolated polypeptide of claim 14, comprising a fragment which comprises at least 200 contiguous amino acids of SEQ ID NO: 2 or SEQ ID NO: 9.

### Claim 16 (depends on 14)

The isolated polypeptide of claim 14, comprising a fragment which comprises at least 400 contiguous amino acids of SEQ ID NO: 2.

### Claim 17 (depends on 14)

The isolated polypeptide of claim 14, comprising a fragment which is at least 90% homologous to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5.

### Claim 18 (depends on 14)

The isolated polypeptide of claim 14, comprising a fragment which is at least 95% homologous to the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5.

### Claim 19 (depends on 14)

The isolated polypeptide of claim 14, comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 5.

### Claim 20 (depends on 14)

The polypeptide of claim 14 further comprising heterologous amino acid sequences.

### Claim 21 (depends on 14)

An antibody which selectively binds to a polypeptide of claim 14.

### Claim 22 (depends on 21)

The antibody of claim 21, which is a monoclonal antibody.

### Claim 23 (depends on 22)

The antibody of claim 22, comprising an immunologically active portion selected from the group consisting of:
a. an scFV fragment;
b. a dcFV fragment;
c. an Fab fragment; and
d. an F(ab′)2 fragment.

### Claim 24 (depends on 22)

The antibody of claim 22, wherein the antibody is selected from the group consisting of:
a. a chimeric antibody;
b. a humanized antibody;
c. a human antibody;
d. a non-human antibody; and
e. a single chain antibody.

### Claim 25 (depends on 11)

A method for producing a polypeptide selected from the group consisting of:
a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9;
b) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9, wherein the fragment comprises at least 100 contiguous amino acids of SEQ ID NO: 2 or SEQ ID NO: 9;
c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 9, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 8, or SEQ ID NO: 10, or a complement thereof under stringent conditions;
comprising culturing the host cell of claim 11 under conditions in which the nucleic acid molecule is expressed.

### Claim 26 (depends on 14)

A method for detecting the presence of a polypeptide of claim 14 in a sample, comprising:
contacting the sample with a compound which selectively binds to a polypeptide of claim 14; and
determining whether the compound binds to the polypeptide in the sample.

### Claim 27 (depends on 25)

The method of claim 25, wherein the compound which binds to the polypeptide is an antibody.

### Claim 28 (depends on 14)

A kit comprising a compound which selectively binds to a polypeptide of claim 14 and instructions for use.

### Claim 29 (depends on 1)

A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of:
contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.

### Claim 30 (depends on 29)

The method of claim 29, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

### Claim 31 (depends on 1)

A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.

### Claim 32 (depends on 14)

A method for identifying a compound which binds to a polypeptide of claim 14 comprising the steps of:
contacting a polypeptide, or a cell expressing a polypeptide of claim 14 with a test compound; and
determining whether the polypeptide binds to the test compound.

### Claim 33 (depends on 32)

The method of claim 32, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of:
a) detection of binding by direct detecting of test compound/polypeptide binding;
b) detection of binding using a competition binding assay; and
c) detection of binding using an assay for 46719 and 46721-mediated signal transduction.

### Claim 34 (depends on 14)

A method for modulating the activity of a polypeptide of claim 14 comprising
contacting a polypeptide or a cell expressing a polypeptide of claim 14 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.

### Claim 35 (depends on 14)

A method for identifying a compound which modulates the activity of a polypeptide of claim 14, comprising:
contacting a polypeptide of claim 14 with a test compound; and
determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.
